TY - JOUR
T1 - Bupropion and naltrexone for smoking cessation
T2 - A double-blind randomized placebo-controlled clinical trial
AU - Mooney, M. E.
AU - Schmitz, J. M.
AU - Allen, S.
AU - Grabowski, J.
AU - Pentel, P.
AU - Oliver, A.
AU - Hatsukami, D. K.
N1 - Publisher Copyright:
© 2016 American Society for Clinical Pharmacology and Therapeutics
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Combination of non-nicotine pharmacotherapies has been underexamined for cigarette smoking cessation. A randomized, double-blind, parallel-group double-dummy study evaluated two medications, bupropion (BUP) and naltrexone (NTX), in treatment-seeking cigarette smokers (N = 121) over a 7-week treatment intervention with 6-month follow-up. Smokers were randomized to either BUP (300 mg/day) + placebo (PBO) or BUP (300 mg/day) + NTX (50 mg/day). The primary outcome was biochemically verified (saliva cotinine, carbon monoxide) 7-day, point-prevalence abstinence. BUP + NTX was associated with significantly higher point-prevalence abstinence rates after 7-weeks of treatment (BUP + NTX, 54.1%; BUP + PBO, 33.3%), P = 0.0210, but not at 6-month follow-up (BUP + NTX, 27.9%; BUP + PBO, 15.0%), P = 0.09. Continuous abstinence rates did not differ, P = 0.0740 (BUP + NTX, 26.2%; BUP + PBO, 13.3%). Those receiving BUP + NTX reported reduced nicotine withdrawal, P = 0.0364. The BUP + NTX combination was associated with elevated rates of some side effects, but with no significant difference in retention between the groups.
AB - Combination of non-nicotine pharmacotherapies has been underexamined for cigarette smoking cessation. A randomized, double-blind, parallel-group double-dummy study evaluated two medications, bupropion (BUP) and naltrexone (NTX), in treatment-seeking cigarette smokers (N = 121) over a 7-week treatment intervention with 6-month follow-up. Smokers were randomized to either BUP (300 mg/day) + placebo (PBO) or BUP (300 mg/day) + NTX (50 mg/day). The primary outcome was biochemically verified (saliva cotinine, carbon monoxide) 7-day, point-prevalence abstinence. BUP + NTX was associated with significantly higher point-prevalence abstinence rates after 7-weeks of treatment (BUP + NTX, 54.1%; BUP + PBO, 33.3%), P = 0.0210, but not at 6-month follow-up (BUP + NTX, 27.9%; BUP + PBO, 15.0%), P = 0.09. Continuous abstinence rates did not differ, P = 0.0740 (BUP + NTX, 26.2%; BUP + PBO, 13.3%). Those receiving BUP + NTX reported reduced nicotine withdrawal, P = 0.0364. The BUP + NTX combination was associated with elevated rates of some side effects, but with no significant difference in retention between the groups.
UR - http://www.scopus.com/inward/record.url?scp=84986538601&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84986538601&partnerID=8YFLogxK
U2 - 10.1002/cpt.402
DO - 10.1002/cpt.402
M3 - Article
C2 - 27213949
AN - SCOPUS:84986538601
SN - 0009-9236
SP - 344
EP - 352
JO - Clinical pharmacology and therapeutics
JF - Clinical pharmacology and therapeutics
ER -